GRIFFIN Study of Dara-RVd Improves HRQOL in R/R Multiple Myeloma

Rebecca Silbermann, MD, MMS, associate professor of medicine at the Division of Hematology/Medical Oncology at Oregon Health & Science University, discusses the findings of the phase 2 GRIFFIN study (NCT02874742) which were presented at the 2022 ASH Annual Meeting.

The study evaluated daratumumab (Darzalex) in addition to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (RVd) induction/consolidation therapy along with lenalidomide maintenance in patients with multiple myeloma.

Findings presented at ASH showed that the combination elicited a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.

Transcription:

0:08 | The GRIFFIN study is a large, randomized, phase 2 study of newly diagnosed myeloma patients who could receive either lenalidomide, bortezomib, dexamethasone, or lenalidomide bortezomib. dexamethasone with daratumumab. In the study, patients got 4 cycles of initial induction therapy, then went to stem cell transplant, had 2 cycles of post-transplant consolidation, and then went on to have maintenance therapy. This abstract was looking at patient reported outcomes that are based on surveys that they completed over the course of the study.

0:41 | What we found was that patients felt better over the course of treatment. We had reductions in fatigue, meaningful reductions in pain, improvements in patient's overall assessment of their quality of life, and there was a signal that there was even better improvement in patients symptoms for those who received daratumumab in combination with the lenalidomide, bortezomib, and dexamethasone. The surveys also continued throughout the maintenance phase of the studies and we were able to see how often patients felt they were getting worse. We found that most of the patients were not reporting worsening of their symptoms. We did not have a meaningful time to first worsening of symptoms themselves.